Q1 2025 Neurocrine Biosciences Inc Earnings Call Transcript
Key Points
- Neurocrine Biosciences Inc (NBIX) reported record new patient starts for INGREZZA in the first quarter, indicating strong market demand.
- The company successfully launched CRENESSITY, achieving $15 million in net revenue with 70% of dispensers receiving reimbursement.
- Neurocrine Biosciences Inc (NBIX) expanded formulary coverage for INGREZZA in Medicare Part D, significantly increasing patient access.
- The company initiated multiple Phase III studies for its pipeline, including osavampator and NBI-'568, demonstrating progress in R&D.
- Neurocrine Biosciences Inc (NBIX) maintains a strong financial position with approximately $1.8 billion in cash, supporting future growth and investment.
- First quarter sales for INGREZZA were impacted by one less order week and patient reauthorization processes, affecting revenue.
- The reauthorization process for continuing patients was more challenging than in previous years, impacting patient retention.
- Gross-to-net dynamics and contracting activities are expected to impact INGREZZA's financial performance in the short term.
- The launch of CRENESSITY is still in its early stages, and long-term adoption and reimbursement trends remain uncertain.
- The Inflation Reduction Act has influenced payer behavior, creating challenges in the reimbursement dynamics for specialty medicines like INGREZZA.
Good day, everyone, and welcome to Neurocrine Biosciences reports first quarter 2025 results. (Operator Instructions) Please note, today's call will be recorded. (Operator Instructions) It is now my pleasure to turn the conference over to Todd Tushla, Vice President of Investor Relations. Please go ahead.
Thank you, and happy Cinco de Mayo to everyone. Welcome to Neurocrine Biosciences first quarter 2025 earnings call. With me today are Kyle Gano, Chief Executive Officer; Matt Abernethy, Chief Financial Officer; Eric Benevich, Chief Commercial Officer; and for one last time as Chief Medical Officer, Eiry Roberts.
During today's call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. Following prepared remarks, we will strive to get to everyone's questions.
Now I will turn the call over to Kyle.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
